Furthermore, continued research on the pharmacokinetics of anti-VEGF agents and the "fellow-eye effect" will be crucial in developing personalized treatment plans, reducing costs, and improving outcomes for patients with AMD. Here, VEGFA is linked to age-related macular degeneration.